X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare JUBILANT LIFE SCIENCES with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

JUBILANT LIFE SCIENCES vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    JUBILANT LIFE SCIENCES LUPIN LTD JUBILANT LIFE SCIENCES/
LUPIN LTD
 
P/E (TTM) x 16.6 27.0 61.6% View Chart
P/BV x 4.4 2.8 155.1% View Chart
Dividend Yield % 0.4 0.6 70.6%  

Financials

 JUBILANT LIFE SCIENCES   LUPIN LTD
EQUITY SHARE DATA
    JUBILANT LIFE SCIENCES
Mar-14
LUPIN LTD
Mar-18
JUBILANT LIFE SCIENCES/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1871,465 12.8%   
Low Rs65727 9.0%   
Sales per share (Unadj.) Rs364.3349.6 104.2%  
Earnings per share (Unadj.) Rs6.85.6 123.2%  
Cash flow per share (Unadj.) Rs24.529.6 82.8%  
Dividends per share (Unadj.) Rs3.005.00 60.0%  
Dividend yield (eoy) %2.40.5 522.1%  
Book value per share (Unadj.) Rs164.9300.3 54.9%  
Shares outstanding (eoy) m159.28452.08 35.2%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x0.33.1 11.0%   
Avg P/E ratio x18.4197.2 9.3%  
P/CF ratio (eoy) x5.137.1 13.9%  
Price / Book Value ratio x0.83.6 20.9%  
Dividend payout %43.890.0 48.7%   
Avg Mkt Cap Rs m20,061495,502 4.0%   
No. of employees `0006.217.0 36.3%   
Total wages/salary Rs m11,05228,647 38.6%   
Avg. sales/employee Rs Th9,383.09,273.6 101.2%   
Avg. wages/employee Rs Th1,786.91,681.0 106.3%   
Avg. net profit/employee Rs Th176.3147.4 119.6%   
INCOME DATA
Net Sales Rs m58,034158,042 36.7%  
Other income Rs m1911,504 12.7%   
Total revenues Rs m58,224159,545 36.5%   
Gross profit Rs m5,78631,475 18.4%  
Depreciation Rs m2,81210,859 25.9%   
Interest Rs m3,2372,044 158.4%   
Profit before tax Rs m-7220,076 -0.4%   
Minority Interest Rs m-286-71 403.4%   
Prior Period Items Rs m035 0.0%   
Extraordinary Inc (Exp) Rs m2,145-14,644 -14.6%   
Tax Rs m6962,885 24.1%   
Profit after tax Rs m1,0902,513 43.4%  
Gross profit margin %10.019.9 50.1%  
Effective tax rate %-965.914.4 -6,722.4%   
Net profit margin %1.91.6 118.2%  
BALANCE SHEET DATA
Current assets Rs m29,280122,095 24.0%   
Current liabilities Rs m38,91250,956 76.4%   
Net working cap to sales %-16.645.0 -36.9%  
Current ratio x0.82.4 31.4%  
Inventory Days Days8485 99.7%  
Debtors Days Days51120 42.3%  
Net fixed assets Rs m55,712129,876 42.9%   
Share capital Rs m155904 17.1%   
"Free" reserves Rs m20,968134,866 15.5%   
Net worth Rs m26,265135,771 19.3%   
Long term debt Rs m17,16964,245 26.7%   
Total assets Rs m88,606263,054 33.7%  
Interest coverage x1.010.8 9.0%   
Debt to equity ratio x0.70.5 138.1%  
Sales to assets ratio x0.70.6 109.0%   
Return on assets %4.91.7 282.0%  
Return on equity %4.21.9 224.3%  
Return on capital %11.63.7 310.9%  
Exports to sales %37.80-   
Imports to sales %16.50-   
Exports (fob) Rs m21,933NA-   
Imports (cif) Rs m9,567NA-   
Fx inflow Rs m22,00453,141 41.4%   
Fx outflow Rs m11,74919,335 60.8%   
Net fx Rs m10,25533,807 30.3%   
CASH FLOW
From Operations Rs m8,02617,512 45.8%  
From Investments Rs m-1,744-14,073 12.4%  
From Financial Activity Rs m-4,447-14,921 29.8%  
Net Cashflow Rs m1,834-11,482 -16.0%  

Share Holding

Indian Promoters % 45.6 46.6 97.9%  
Foreign collaborators % 3.5 0.2 1,750.0%  
Indian inst/Mut Fund % 8.7 11.3 77.0%  
FIIs % 21.2 31.9 66.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.1 10.1 208.9%  
Shareholders   23,815 98,259 24.2%  
Pledged promoter(s) holding % 15.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare JUBILANT LIFE SCIENCES With:   GSK PHARMA  NATCO PHARMA  BIOCON LTD  SANOFI INDIA  PANACEA BIOTECH  

Compare JUBILANT LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets End Lower; Metal Stocks Top Losers(Closing)

Indian share markets settled lower today led by a fall in the financial stocks after the rupee hit a record low of 70.32 per dollar.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

More Views on News

Most Popular

How to Make Big Profits by Following India's Best Investors(The 5 Minute Wrapup)

Aug 3, 2018

In a time when stocks recommended by so-called 'gurus of the market' are crashing, let Kunal Thanvi guide you to the best gurus...and their best stocks.

The Biggest Mistake You Can Make in this Market (and 3 Stocks to Buy Now!)(Profit Hunter)

Aug 3, 2018

This price pattern can help you identify stocks on the verge of a turnaround.

Does This Indicator Tell Us the Sensex is Headed for a Correction?(Vivek Kaul's Diary)

Aug 3, 2018

To what extent have foreign flows influenced Indian stock markets? How do we see it panning out now?

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

JUBILANT LIFE SCIENCES SHARE PRICE


Aug 16, 2018 (Close)

TRACK JUBILANT LIFE SCIENCES

  • Track your investment in JUBILANT LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON JUBILANT LIFE SCIENCES

JUBILANT LIFE SCIENCES 5-YR ANALYSIS

COMPARE JUBILANT LIFE SCIENCES WITH

MARKET STATS